A Study of PET/CT Scans With the Radioactive Tracer 89Zr-DFO-Daratumumab in People With Myeloma

NCT04467281 · clinicaltrials.gov ↗

PHASE2

Phase

WITHDRAWN

Status

OTHER

Sponsor class

Stopped PI left institution and study is being transferred.

Conditions

Multiple Myeloma

Interventions

DRUG: 89Zr-DFO-daratumumab
DIAGNOSTIC_TEST: PET/CT

Sponsor

Memorial Sloan Kettering Cancer Center